PSMA6P3

Across TCGA pan-cancer cohorts, PSMA6P3 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated PSMA6P3 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher PSMA6P3 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PSMA6P3 expression acts as an unfavorable survival marker.

CHOL, LIHC, and STAD are the cancer types where PSMA6P3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.019	0.800	<.001	72	view →
LIHC	DFS	Tertile	All	0.078	0.555	<.001	72	view →
STAD	DFS	Tertile	All	0.173	0.430	.001	57	view →
KICH	OS	Tertile	All	0.082	0.877	<.001	51	view →
BRCA	OS	Tertile	III,IV	0.814	0.911	.010	45	view →
KIRC	DFS	Tertile	IV	0.227	0.633	.001	36	view →
CESC	OS	Tertile	IV	0.091	0.593	<.001	36	view →
SKCM	DFS	Tertile	All	0.585	0.742	.013	33	view →
OV	DFS	Tertile	All	0.258	0.386	.035	24	view →
COAD	DFS	Tertile	II,III,IV	0.172	0.502	.010	18	view →
ACC	OS	Tertile	All	0.147	0.685	.018	18	view →
THCA	OS	Tertile	IV	0.751	1.000	.014	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

PSMA6P3–CHOL (OS)

Open the CHOL breakdown →